Moderna, Inc. MRNA shares are trading higher in sympathy with Pfizer and BioNTech following reports indicating the FDA is expected to fully approve Pfizer and BioNTech's COVID-19 vaccine.
Reports also suggest the FDA said Pfizer-BioNTech's COVID-19 vaccine will now be marketed as comirnaty, for prevention of COVID-19 disease in individuals 16 years of age & older.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases.
Moderna's stock was trading about 5.5% higher at $404.01 per share Monday morning at the time of publication. The stock has a 52-week high of $497.49 and a 52-week low of $54.21.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
